BioNxt Solutions Inc.
17.7.2024 09:07:24 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESSWIRE / July 17, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a statement of work ("SOW") with a German-based international contract research, development, and manufacturing organization (the "CRDMO"). The SOW is focused on the Company's flagship Cladribine oral dissolvable film ("ODF") development program.
The SOW sets out a number of important deliverables, including but not limited to technology transfer and implementation, evaluation batch production (GMP material under GMP conditions), stability testing, cGMP manufacturing of clinical study samples, and preparation of the PK study Investigational Medical Product Dossier for EU submission.
BioNxt is developing a 100% owned and proprietary ODF Cladribine dosage form, directed at the multiple sclerosis ("MS") market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with annual sales in excess of one billion USD. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS and certain forms of leukemia. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
The CRDMO has a head office in Munich, Germany, with an international network of pharmaceutical service providers with facilities in five countries and over 500 employees. They offer GCP/GLP/GMP/ISO/IEC-certified services and GMP certified manufacturing of clinical trial supplies (Phase I-III) with a specialization in solids, semi-solids, liquids, oral films, and transdermal patches as well as integrated lab analytical services during development & GMP manufacturing, including API characterization, method development, optimization, validation, permeation studies, stabilities studies, etc.
The Company has filed Cladribine ODF-related provisional patent applications with three to four patent applications expected to be on file in major international jurisdictions by late 2024 to early 2025 with potential patent protection extending to 2044.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Study Finds Lower Rates of Overweight Among Vegan-Fed Cats23.10.2026 16:45:00 CEST | Press release
LONDON, UK / ACCESS Newswire / October 23, 2026 / A large-scale survey published in Frontiers in Animal Science has found cats fed vegan diets had lower rates of obesity and related health problems, than those fed conventional meat-based diets. An online survey analysed carer-reported veterinary assessments of 1,305 cats fed either conventional meat-based (90%) or vegan (10%) diets for at least one year. After accounting for factors including age, sex, neuter status, activity and feeding practices, vegan-fed cats had 34% lower odds of being assessed as overweight. However, the difference was not statistically significant, in part reflecting the relatively small number of vegan-fed cats. For several body weight-related problems, no vegan-fed cats were affected. Nevertheless, researchers say the findings show an interesting trend that warrants further investigation. Overweight and obesity are common in domestic cats, with veterinary studies estimating that around 30-60% of cats are overw
Leggett Dynamics's Mid-Class Massage System Wins Gasgoo's Best Technical Practice Award23.10.2026 16:00:00 CEST | Press release
SHANGHAI, CHINA / ACCESS Newswire / October 23, 2026 / Leggett Dynamics today announced that its Mid-Class Massage System (MCM) received Gasgoo's Best Technical Practice Award during a ceremony held at the 14th annual Automotive & Environment Innovation Forum in Shanghai. The Gasgoo Best Technical Practice Award honors automotive technologies that have proven innovation, production readiness and measurable customer value in real-world vehicle applications. The judging panel cited MCM's innovation that achieves affordable, premium-level comfort for mid-class vehicle programs. About Leggett Dynamics' Mid-Class Massage System Leggett Dynamics' MCM is a comfort innovation that expands premium massage technology beyond the luxury vehicle segment. Already in serial production with a leading global OEM and generating strong interest from multiple global automakers, the innovation delivers a premium massage experience while reducing system cost and complexity through the intelligent use of pre
New Global Initiative Seeks to Modernize Health Workforce Mobility22.10.2026 17:00:00 CEST | Press release
PHILADELPHIA, PA, TORONTO, ON AND GRONINGEN, NETHERLANDS / ACCESS Newswire / October 22, 2026 / TruMerit® and Centennial College, with support of the Groningen Declaration Network (GDN Network), have unveiled a new vision for the future of global health workforce mobility, introducing a framework designed to help health professionals carry trusted, verifiable records of their qualifications and competencies across borders. The initiative is detailed in a newly published paper titled "Toward a Global Digital Credential Mobility Ecosystem for Migrating Health Professionals." As healthcare systems worldwide face persistent workforce shortages, internationally educated health professionals often encounter lengthy, duplicative, and inconsistent credential recognition processes that can delay entry into practice. The paper proposes a new approach centered on a Global Competency Record (GCR). This portable digital record could securely bring together verified evidence of a professional's educ
P&G, Nestlé, Mars, AstraZeneca, ITC and Bekaert win OMP Supply Chain Awards22.10.2026 15:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / October 22, 2026 / OMP, a leader in AI-powered supply chain solutions, recently honored six global brands at its conferences held earlier this month in Singapore and Shanghai. The recognized companies - Procter & Gamble (P&G), Nestlé, Mars, AstraZeneca, ITC, and Bekaert - were celebrated for driving decision velocity, co-innovation, and impactful business results. Supply Chain Innovation & Excellence Award: Nestlé and Bekaert Nestlé, one of the world's largest food and beverage companies, and Bekaert, a global market and technology leader in material science of steel wire transformation and coating technologies, received OMP's Supply Chain Innovation & Excellence award for their breadth of deployment and depth of co-innovation.Nestlé aligns its supply network at the strategic, tactical, and operational levels on OMP's Unison Planning™ platform, connecting forecasting, planning, and replenishment end-to-end. As more routine work becomes touchless, plann
Karbon-X (OTCQB:KARX) Accelerates High-Margin Transformation in Q1 FY2027: Gross Margin Expands to 32%, Operating Cash Burn Drops 55%, and Deferred Revenue Reaches $4.3 Million22.10.2026 13:45:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / October 22, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced its financial and operational results for the first quarter of fiscal 2027 (ended August 31, 2026), following the filing of its Quarterly Report on Form 10-Q. The quarter was highlighted by a significant expansion in gross margin to 32%, a 55% reduction in net operating cash use, and continued momentum across international project development and advisory engagements. Through disciplined execution, Karbon-X has shifted its commercial mix toward higher-margin, value-added environmental consulting and project commercialization, strengthening its operational foundation for sustainable, long-term growth. First Quarter Fiscal 2027 HighlightsSubstantial Gross Margin Expansion: Gross margin rose to 32%, compared with 0.8% in the prior-year period, reflecting a higher-margin revenue mix centered on technical advisory an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom